Updated August 2026. Establishing a pharmaceutical manufacturing company in the UAE places your business at the crossroads of one of the Middle East’s most regulated and highest-growth industrial sectors. The UAE pharmaceutical market reached AED 18.5 billion (USD 5 billion) in 2025 and is projected to expand to AED 27.6 billion (USD 7.5 billion) by 2030, driven by UAE Vision 2031 industrial targets, rising domestic healthcare demand, and strategic export access to 100+ countries. This comprehensive guide covers every regulatory step, capital requirement, and location decision you need to launch a fully compliant UAE pharmaceutical manufacturing facility in 2026.
- MOHAP (Ministry of Health and Prevention) issues the federal pharmaceutical manufacturing license and oversees WHO-GMP certification for all production facilities.
- DCAA (Drug Control Authority and Administration) provides emirate-level drug control approval, mandatory for any facility producing or distributing within Dubai jurisdiction.
- Facility capital investment ranges from AED 50 million for a basic oral solid dosage (OSD) line to AED 500 million for a multi-product sterile injectable facility.
- Dubai Science Park (DSP) and KIZAD (Khalifa Industrial Zone Abu Dhabi) offer the most established GMP-ready pharmaceutical free zone clusters in the Gulf.
- UAE-manufactured pharmaceuticals qualify for zero-duty GCC trade under GAFTA, with additional preferential access via UAE-India CEPA and UAE-Israel CEPA.
UAE Pharmaceutical Manufacturing Sector: Market Overview 2026
The UAE is home to more than 45 licensed pharmaceutical manufacturers as of mid-2026, with combined production capacity exceeding AED 4.2 billion annually. The sector receives significant government support under the UAE National Pharmaceutical Programme, which targets producing 300 essential medicines domestically by 2031. The GCC pharmaceutical market—valued at USD 6.4 billion in 2025—relies heavily on UAE-based manufacturers for generics, OTC products, and specialty biologics.
Key demand drivers include a UAE resident population of 10.5 million with high per-capita healthcare spending (AED 6,800 per person annually), a rapidly growing medical tourism sector, and increasing government mandates for local production of critical medicines. The UAE’s strategic location—within a 4-hour flight of 2.5 billion people across MENA, Africa, and South Asia—makes UAE-based manufacturing a natural regional hub.
The sector benefits from the UAE’s zero corporate tax on qualifying pharmaceutical manufacturing income within designated free zones, strong IP protection under UAE Federal Law No. 31 of 2006, and a growing network of bilateral trade agreements. For investors considering UAE company formation requirements, pharmaceutical manufacturing offers one of the highest potential returns among industrial sectors.
MOHAP Pharmaceutical Manufacturing License: Requirements and Process
The Ministry of Health and Prevention (MOHAP) is the primary federal authority for pharmaceutical manufacturing licensing in the UAE under Federal Law No. 4 of 1983 (Pharmaceutical Practice Law) and its subsequent amendments through Cabinet Resolution No. 60 of 2020. A MOHAP manufacturing license is mandatory for any entity producing, packaging, labelling, or repackaging pharmaceutical products within the UAE.
The MOHAP licensing process requires: (1) a pre-application meeting with the Drug Department to discuss facility scope, product categories, and GMP readiness; (2) submission of a complete dossier including company incorporation documents, facility master plan, equipment list, quality management system documentation, and SOPs for all critical manufacturing processes; (3) a site readiness inspection conducted by MOHAP inspectors within 60–90 days of dossier acceptance; (4) GMP certification issuance following successful inspection; and (5) product-specific manufacturing authorization for each drug to be produced.
Timeline: MOHAP licensing typically requires 12–24 months from dossier submission to first manufacturing authorization, depending on facility complexity and documentation quality. Fees range from AED 15,000 for initial application to AED 50,000 for multi-site or complex facility licenses. Annual renewal fees apply at AED 10,000–25,000.
MOHAP inspects against WHO Technical Report Series (TRS) 986 Annex 2 GMP guidelines, which form the minimum standard. Facilities targeting EU or US market exports must additionally comply with EU GMP Annex 1 (sterile products) or FDA 21 CFR Part 211 requirements, which MOHAP increasingly accommodates through equivalence agreements.
DCAA Drug Control Authority: Emirate-Level Approval Framework
The Drug Control Authority and Administration (DCAA) operates at the emirate level in Dubai, working in coordination with MOHAP to regulate the manufacture, import, export, and distribution of pharmaceutical products within Dubai’s jurisdiction. Any pharmaceutical manufacturing facility located in Dubai—whether on the mainland or within a Dubai-administered free zone such as Dubai Science Park—requires DCAA approval in addition to the federal MOHAP license.
DCAA registration covers controlled substances licensing (Schedules I–IV under UAE Cabinet Resolution No. 38 of 2014), narcotics and psychotropic substances authorization, pharmaceutical wholesale distribution permits, and Good Distribution Practice (GDP) certification. DCAA also oversees the Emirates Good Manufacturing Practice (EGMP) audit program for locally manufactured products intended for domestic distribution.
DCAA application requirements include: copy of MOHAP manufacturing license, facility layout drawings, product list with registration numbers, qualified person (QP) declaration, and pharmacovigilance system master file (PSMF). The DCAA review process takes 4–8 weeks following submission of a complete application package. Annual DCAA registration fees range from AED 5,000 to AED 30,000 depending on product categories and controlled substance schedules involved.
Free Zone Options: Dubai Science Park vs KIZAD vs Sharjah Healthcare City
The UAE offers three primary pharmaceutical manufacturing free zones, each with distinct advantages based on product category, target market, and investment scale:
| Free Zone | Emirate | Min. Land Area | GMP-Ready Units | Annual Rent (AED/sqm) |
|---|---|---|---|---|
| Dubai Science Park (DSP) | Dubai | 500 sqm | Yes | AED 280–450 |
| KIZAD (Abu Dhabi) | Abu Dhabi | 2,500 sqm | Shell-and-core | AED 120–220 |
| Sharjah Healthcare City (SHCC) | Sharjah | 1,000 sqm | Partial | AED 180–320 |
| Fujairah Free Zone | Fujairah | 5,000 sqm | Build-to-suit | AED 85–150 |
Dubai Science Park (DSP) is the most established pharmaceutical cluster in the UAE, hosting 250+ life sciences companies including Julphar, Tabuk Pharmaceuticals, and Novartis. DSP’s Pharmaceutical Manufacturing Zone offers pre-built GMP-compliant shell units, shared utilities (purified water systems, HVAC with ISO classification, hazardous waste disposal), and dedicated regulatory liaison services with MOHAP and DCAA. For investors seeking UAE free zone comparison across sectors, DSP consistently ranks highest for pharmaceutical-specific infrastructure.
KIZAD (Khalifa Industrial Zone Abu Dhabi) is the preferred location for large-scale, capital-intensive manufacturing targeting API (Active Pharmaceutical Ingredient) production and bulk dosage form manufacturing. KIZAD offers significantly lower land lease rates (AED 120–220/sqm vs DSP’s AED 280–450/sqm), build-to-suit industrial plots from 2,500 sqm, and direct port access to Khalifa Port for bulk import of raw materials and export of finished goods. KIZAD facilities operating under ADIO’s industrial incentive program qualify for 0% corporate tax under UAE corporate tax free zone provisions through 2035.
Facility Capital Investment: AED 50M–500M Breakdown
Pharmaceutical manufacturing facility investment in the UAE spans a wide range depending on product category, production scale, and GMP standard target:
Tier 1 — Solid Dosage Forms (Tablets/Capsules): AED 50M–120M. A 5,000 sqm OSD (Oral Solid Dosage) facility producing 500 million tablets annually requires granulation suites, tablet compression rooms (ISO 8), coating equipment, and packaging lines. Construction of pharma-grade clean rooms in the UAE costs AED 4,500–8,000/sqm depending on ISO classification. Equipment import from Germany, Italy, or China adds AED 20M–40M for a mid-scale OSD line.
Tier 2 — Liquid and Semi-Solid Products: AED 80M–200M. Syrup, suspension, cream, and ointment manufacturing requires stainless steel mixing vessels, homogenizers, and filling lines with CIP/SIP systems. A 10,000-litre batch capacity liquid facility typically costs AED 80M–150M all-in.
Tier 3 — Sterile Injectable Products: AED 200M–500M. Vial, ampoule, and pre-filled syringe manufacturing under ISO 5/7 cleanroom conditions represents the highest capital category. A sterile injectables facility with lyophilization capability requires AED 150M–300M in specialized construction and AED 80M–200M in equipment.
Ongoing operational costs include QA staff (a QP with 10+ years experience commands AED 35,000–60,000/month), raw material procurement (subject to MOHAP import permits), and annual GMP re-inspection fees. Working capital requirements for the first 24 months of operations typically add AED 20M–50M to the total investment.
WHO-GMP Certification: Process, Timeline, and Audit Scope
GMP (Good Manufacturing Practice) certification is the central compliance requirement for UAE pharmaceutical manufacturers. MOHAP grants GMP certificates following a successful on-site inspection of the facility, conducted against WHO TRS 986 Annex 2 guidelines. The GMP certification process involves five stages: documentation review, pre-inspection readiness assessment, MOHAP site inspection (typically 3–5 days for a medium-complexity facility), observation response and CAPA submission, and certificate issuance.
Critical GMP areas inspected include: personnel qualification and training records, premises and equipment qualification (IQ/OQ/PQ protocols), raw material testing and release procedures, in-process controls and finished product testing, stability study protocols, deviation and CAPA management system, recall procedure documentation, and annual product review (APR) system.
GMP certificates are valid for 3 years, with annual surveillance inspections in year 2. Facilities targeting EU export must obtain EU GMP certification from an EU/EEA competent authority (most UAE manufacturers use MHRA-UK or German TGA equivalents through bilateral arrangements). FDA approval requires a separate US FDA pre-approval inspection (PAI) for each ANDA or NDA product dossier.
Ongoing Compliance and Export Pathways
UAE pharmaceutical manufacturers benefit from a robust export framework. MOHAP issues Free Sale Certificates (FSC) and Certificate of Pharmaceutical Products (CPP) required by importing country regulators. The UAE is a member of the Pharmaceutical Inspection Co-operation Scheme (PIC/S) since 2014, meaning MOHAP GMP certificates are recognized by 55 member countries, significantly reducing the burden of foreign regulatory submissions.
UAE manufacturers exporting to GCC markets (Saudi Arabia, Kuwait, Bahrain, Qatar, Oman) operate under the GCC Technical Regulations for pharmaceuticals, coordinated through the Gulf Health Council. GCC registration typically takes 6–18 months per product, with mutual recognition agreements reducing timelines for products already registered in the UAE.
For manufacturers seeking the optimal tax structure for pharmaceutical export operations, UAE company formation requirements cover the specific legal structures—including free zone LLC, PJSC, and branch office models—that optimize duty and tax exposure across the export supply chain.
What is the minimum investment required for a UAE pharmaceutical manufacturing facility?
The minimum viable pharmaceutical manufacturing investment in the UAE is approximately AED 50 million (USD 13.6 million) for a small-scale oral solid dosage (OSD) facility producing tablets and capsules. This covers GMP-compliant construction (AED 15M–20M), manufacturing equipment (AED 20M–25M), utility systems including purified water and HVAC (AED 5M–8M), and initial working capital. Sterile injectables and biologics facilities require AED 200M–500M.
Do UAE pharmaceutical manufacturers need separate licenses from MOHAP and DCAA?
Yes. MOHAP issues the federal pharmaceutical manufacturing license covering GMP compliance and product manufacturing authorization at the national level. DCAA approval is required at the emirate level for facilities operating in Dubai jurisdiction. Manufacturers in Abu Dhabi engage DOH (Department of Health Abu Dhabi) for emirate-level oversight instead of DCAA. Both licenses are mandatory and must be maintained simultaneously through annual renewals and inspection compliance.
Can a foreign company own 100% of a UAE pharmaceutical manufacturing company?
Yes. UAE Federal Law No. 26 of 2020 (Foreign Direct Investment Law) permits 100% foreign ownership of pharmaceutical manufacturing companies on the UAE mainland in designated strategic sectors. Free zone companies inherently allow 100% foreign ownership. However, products registered for domestic UAE sale require a UAE-national Authorized Representative (pharmacist licensee) under MOHAP regulations, which is a representative role distinct from share ownership.
How long does WHO-GMP certification take in the UAE?
From facility construction completion to GMP certificate issuance typically takes 12–18 months. This includes 3–6 months for equipment qualification (IQ/OQ/PQ), 3–6 months for process validation and stability initiation, 2–4 months for MOHAP dossier review, and 4–8 weeks for on-site inspection scheduling and completion. Facilities with well-prepared quality documentation consistently achieve certification at the lower end of this range.
Which UAE free zone offers the best infrastructure for pharmaceutical manufacturing?
Dubai Science Park (DSP) offers the most comprehensive pharmaceutical infrastructure with pre-built GMP shell units, shared utility systems, on-site MOHAP liaison, and an established cluster of 250+ life sciences companies. For large-scale API or bulk manufacturing with lower operating costs, KIZAD (Abu Dhabi) provides superior land economics with direct port access. Sharjah Healthcare City suits smaller specialty manufacturers and R&D-focused operations. Free zone selection should be aligned with product category, scale, and primary export market.